Barclays’s Replimune Group REPL Stock Holding History

Barclays’s Portfolio REPL Stock Details REPL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.5M	Buy	315,900 +70,900	+29%	+$434K	﹤0.01%	2033
2026 Q1	$1.87M	Buy	+245,000	New	+$1.87M	﹤0.01%	2389
2025 Q4	–	Sell	-37,000	Closed	-$155K	–	5598
2025 Q3	$155K	Sell	37,000 -38,900	-51%	-$249K	﹤0.01%	4441
2025 Q2	$705K	Buy	+75,900	New	+$662K	﹤0.01%	3560

Other funds holding REPL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

RCI

Ridgeback Capital Investments Miami Beach, Florida $80.9M AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Barclays's REPL Position: Q2 2026 in Review

Barclays increased its Replimune Group (REPL) stake by 153% in Q2 2026, buying an estimated $841K and bringing the position to 227,063 shares worth $2.51M. The position accounts for ﹤0.01% of the portfolio, ranked #2222.

Barclays first reported a position in REPL in Q3 2018 and has held it in 32 quarters since. The position peaked at $3.46M in Q2 2025. 199 funds tracked by Wall St. Rank hold REPL as of Q2 2026.

Barclays held 227,063 shares of Replimune Group worth $2.51M as of Q2 2026.
Barclays bought 137,441 Replimune Group shares in Q2 2026, an estimated $841K.
Replimune Group made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2222 holding.
Barclays first reported a position in Replimune Group in Q3 2018 and has held it in 32 quarters since.
Barclays's Replimune Group position peaked at $3.46M in Q2 2025.
199 funds tracked by Wall St. Rank held Replimune Group as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.